Peter J. Trainer, MD

Crinetics Pharmaceuticals
San Diego, California, United States

Disclosure information not submitted.

Presentation(s):

• ORF28-06 - Efficacy and Safety of Once-Daily Oral Paltusotine in Patients with Acromegaly: Up to 2 Years in the PATHFNDR-1 and PATHFNDR-2 Open-Label Extension Studies

  Sunday, June 14, 2026
  2:30 PM - 2:45 PM CT

• ORF32-04 - Once Daily Atumelnant (CRN04894) Enables Lowering of Glucocorticoid Doses with Sustained Androgen Reduction in Adults with Congenital Adrenal Hyperplasia

  Sunday, June 14, 2026
  2:10 PM - 2:25 PM CT

• ORF35-04 - BLOCK AND REPLACE' ATUMELNANT (CRN04894) AND PHYSIOLOGIC HYDROCORTISONE REPLACEMENT RAPIDLY CONTROLS HYPERCORTISOLISM IN ACTH-DEPENDENT CUSHING SYNDROME

  Sunday, June 14, 2026
  3:45 PM - 4:00 PM CT